Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis

Opinion
Video

An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.

Video Player is loading.
Current Time 0:00
Duration 4:54
Loaded: 0%
Stream Type LIVE
Remaining Time 4:54
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Content